foxo4-dri peptide senolytic human trial Molecular modelling of the FOXO4-TP53 interaction to design peptides for the elimination of senescent cancer cells Frontiers | FOXO4-DRI regulates endothelial
Frontiers FOXO4 DRI regulates endothelial cell senescence via the P53 signaling pathway Molecular modelling of the FOXO4 TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells eBioMedicine FOXO4 DRI Peptide 10 mg FOXO4 DRI Vial 10mg Stemcode Peptides The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications
Pay in 4 interest-free payments of $6.34 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6




